FIBRIN‐DERIVED PEPTIDES AND PULMONARY INJURY
1982; Wiley; Volume: 384; Issue: 1 Linguagem: Inglês
10.1111/j.1749-6632.1982.tb21381.x
ISSN1749-6632
Autores Tópico(s)Mechanical Circulatory Support Devices
ResumoAnnals of the New York Academy of SciencesVolume 384, Issue 1 p. 319-331 FIBRIN-DERIVED PEPTIDES AND PULMONARY INJURY Tom Saldeen, Tom Saldeen Institute of Forensic Medicine University of Uppsala S-752 37 Uppsala, SwedenSearch for more papers by this author Tom Saldeen, Tom Saldeen Institute of Forensic Medicine University of Uppsala S-752 37 Uppsala, SwedenSearch for more papers by this author First published: May 1982 https://doi.org/10.1111/j.1749-6632.1982.tb21381.xCitations: 20AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Saldeen, T. 1979. The microembolism syndrome. In The Microembolism Syndrome. T. Saldeen, Ed.: 7–44. Almqvist & Wiksell International. Stockholm , Sweden . 2 Busch, C., S. Dahlgren, S. Jakobson, B. Jung, J. Modig & T. Saldeen. 1975. The use of 125I-labelled fibrinogen for determination of fibrin trapping in the lungs in patients developing the microembolism syndrome. Acta Anaesthesiol. Scand. 57: 46–54. 3 Saldeen, T. 1976. The microembolism syndrome. Microvasc. Res. 11: 227–259. 4 Wallin, R., M. Belew, B. Gerdin & T. Saldeen. 1980. Differential degradation by plasmin of fragment E derived from fibrin and fibrinogen. Thromb. Res. 19: 441–445. 5 Sandler, H. & T. Saldeen. 1981. Effect of an inhibitor of thromboxane synthesis (UK-37, 248–01) on thrombin-induced pulmonary insufficiency in the rat. Thromb. Haemostasis 46: 279. 6 Smedegård, G., B. Revenäs & T. Saldeen. 1980. Anaphylaxis in the monkey: haemotological and histological findings. Int. Arch. Allergy Appl. Immunol. 61: 117–124. 7 Revenäs, B., G. Smedegård & T. Saldeen. 1980. The pulmonary reaction in aggregate anaphylaxis in the monkey. Acta Chir. Scand. Suppl. 499: 161–169. 8 Lindquist, O., L. Rammer & T. Saldeen. 1972. Pulmonary insufficiency, microembolism and fibrinolysis inhibition in a posttraumatic autopsy material. Acta Chir. Scand. 138: 545–549. 9 Bagge, L., I. Björk, T. Saldeen & R. Wallin. 1976. Purification and characterization of an inhibitor of plasminogen activation from posttraumatic patients. Forensic Sci. 7: 83–86. 10 Saldeen, T., L. Bagge, H. Jacobsson & R. Wallin. 1977. Purification and characterization of a fibrinolysis inhibitor. Forensic Sci. 10: 149–151. 11 Bagge, L., I. Björk, T. Saldeen & R. Wallin. 1978. Purification of a fibrinolysis inhibitor in serum from posttraumatic patients. Thromb. Haemostasis 39: 97–108. 12 Bagge, L. & T. Saldeen. 1978. The primary fibrinolysis inhibitor and trauma. Thromb. Res. 13: 1131–1136. 13 Bagge, L., U. Hedstrand, M. HÖök, S. JOHANSSONÖök, E. Lind, J. Mode & T. Saldeen. 1979. Fibrinolysis inhibition and fibronectin in the blood in patients with the delayed microembolism syndrome. Acta Univ. Ups. Abstr. Upps. Diss. Fac. Med. No. 342. 14 Arfors, K-E., C. Busch, S. Jakobson, O. Lindquist, P. Malmberg, L. Rammer & T. Saldeen. 1972. Pulmonary insufficiency following intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog. Acta Chir. Scand. 138: 445–452. 15 Gerdin, B., C. Diffang & T. Saldeen. 1982. Pulmonary insufficiency in the rat after intravascular coagulation and inhibition of fibrinolysis. I. Studies on some pathogenetic mechanisms. Eur. Surg. Res. (In press.). 16 Lindquist, O., T. Saldeen & H. Sandler. 1976. Pulmonary damage following pulmonary microembolism in the dog. Effect of various types of treatment. Acta Chir. Scand. 142: 15–19. 17 Busch, C., O. Lindquist & T. Saldeen. 1974. Respiratory insufficiency in the dog induced by pulmonary microembolism and inhibition of fibrinolysis. Effect of defibrinogenation, leucopenia and thrombocytopenia. Acta Chir. Scand. 140: 255–266. 18 Saldeen, T. 1980. Fibrin derived peptides as mediators of increased vascular permeability. Acta Chir. Scand. Suppl. 499: 67–72. 19 Staub, N. C., K. Ohkuda, K. Nakahara, V. J. Weidner & A. Binder. 1979. The effect of uneven pulmonary artery obstruction in sheep on lung fluid balance. In The Microembolism Syndrome. T. Saldeen. Ed.: 201–212. Almqvist & Wiksell International. Stockholm , Sweden . 20 MoCostabella, P., O. Lindquist, Y. Kapanci & T. Saldeen. 1978. Increased vascular permeability in the delayed microembolsim syndrome. Experimental and human findings. Microvasc. Res. 15: 275–286. 21 Gerdin, B., H. Sandler & T. Saldeen. 1982. Pulmonary insufficiency in the rat after intravascular coagulation and inhibition of fibrinolysis. II. Investigations on oedema formation and morphology. Eur. Surg. Res. (In press.). 22 Belew, M., B. Gerdin, J. Porath & T. Saldeen. 1978. Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thromb. Res. 13: 983–994. 23 Wallin, R., M. Belew, K. Ohlsson & T. Saldeen. 1981. Purification of vasoactive peptides from human fibrinogen degraded by human leukocyte elastase. Thromb. Haemostasis 46: 52. 24 Lindquist, O., B. Gerdin, T. Saldeen & E. Svensjö. 1975. Demonstration of a permeability increasing factor in interstitial fluid from the lung following thrombin induced pulmonary microembolism in the dog and the rat. Microvasc. Res. 10: 238. 25 Gerdin, B., M. Belew, O. Lindquist & T. Saldeen. 1979. Effect of a fibrin derived peptide on pulmonary microvascular permeability. In The Microembolism Syndrome. T. Saldeen, Ed.: 233–239. Almqvist & Wiksell International. Stockholm , Sweden . 26 Gerdin, B. & T. Saldeenerdin. 1978. Effect of fibrin degradation products on microvascular permeability. Thromb. Res. 13: 995–1006. 27 Belew, M., B. Gerdin, G. Lindeberg, J. Porath, T. Saldeen & R. Wallin. 1980. Structure-activity relationship of vasoactive peptides derived from fibrin or fibrinogen degraded by plasmin. Biochim. Biophys. Acta 621: 169–178. 28 Belew, M., B. Gerdin, L-E. Larsson, G. Lindeberg, U. Ragnarsson, T. Saldeen & R. Wallin. 1980. Structure-activity studies on synthetic analogs of vasoactive peptides derived from human fibrinogen. Biochim. Biophys. Acta 632: 87–94. 29 Gerdin, B., G. Lindeberg, U. Ragnarsson, T. Saldeen & R. Wallin. 1981. Structural similarities between synthetic analogs to a vasoactive peptide derived from human fibrinogen and other biologically active peptides. Progress in Fibrinolysis 5: 385–389. Churchill Livingstone. Edinburgh , Scotland . 30 Saldeen, T., J. W. Ryan & P. Berryer. 1981. A peptide derived from fibrin(ogen) inhibits angiotensin converting enzyme and potentiates the effects of bradykinin. Thromb. Res. 23: 465. 31 Eriksson, M., B. Gerdin & T. Saldeen. 1981. Enhancement of the microcirculatory leakage due to decreased extravascular inactivation of bradykinin by a peptide derived from fibrinogen. Thromb. Haemostasis 46: 695. 32 Gerdin, B., L. Juhlin & T. Saldeen. 1981. Cutaneous reaction to two fibrin derived peptides. Acta Dermatoveneriol. [Stockholm] 61: 558–560. 33 Kopeć, M., W. Roszkowski, S. Szmigielski, B. Gerdin & T. Saldeen. 1979. Effect of low molecular weight fibrinogen degradation products on lymphocytes, macrophages and kidney cells in cultures. Thromb. Haemostasis 42: 293. 34 Gerdin, B., T. Saldeen, W. Roszkowski, S. Szmigielski, J. Stachurska & M. Kopeć. 1980. Immunosuppressive effect of vasoactive peptides derived from human fibrinogen. Thromb. Res. 18: 461–468. 35 Roszkowski, W., J. Stachurska, H. Gerdin, T. Saldeen & M. Kopeć. 1981. Suppression of cell-mediated immune reactivity by peptides cleaved from fibrinogen. [Submitted for publication.). 36 Roszkowski, W., J. Stachurska, B. Gerdin, T. Saldeen & M. Kopeć. 1981. Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 sarcoma in BALB/c mice. Eur. J. Cancer Clin. Oncol. 17: 889–892. 37 Saldeen, T. [Unpublished.]. 38 Carlin. G., J. Mode & T. Saldeen. 1979. Effect of infusion of dextran 70 on fibrinolysis inhibition activity in serum in man. Acta Chir. Scand. 145: 129–131. 39 Carlin, G. & T. Saldeen. 1980. On the interaction between dextran and the primary fibrinolysis inhibitor α2-antiplasmin. Thromb. Res. 19: 103–110. 40 Gruber, U. F., T. Saldeen, T. Brokop, B. Eklöf, I. Eriksson, I. Goldie, L. Gran, M. Hohl, T. Jonsson, S. Kristersson, K. G. Liungström, T. Lund, H. Maartman Moe, E. SVENSJÖ, D. Thomson, J. Torhorst, A. Trippestad & M. Ulstein. 1980. Comparison of the incidence of fatal postoperative pulmonary embolism with dextran 70 or low dose heparin prophylaxis. An international multicentre study. Br. Med. J. 280: 69–77. Citing Literature Volume384, Issue1Mechanisms of Lung Microvascular InjuryMay 1982Pages 319-331 ReferencesRelatedInformation
Referência(s)